Gender Transition Regret: The Growing Scandal They're Trying to Hide

 

There is a conversation happening in hospital corridors, in courtrooms, in therapy offices, and in the bedrooms of thousands of young people who made life-altering decisions, and now wish they hadn't.

It is a conversation that powerful institutions have tried, with remarkable persistence, to suppress.

But the dam is cracking.

Gender transition regret, once dismissed as a fringe phenomenon affecting a negligible minority, is emerging as one of the most uncomfortable medical and ethical stories of the 21st century. The evidence is piling up. The voices are growing louder. And the silence from the medical establishment is becoming harder to justify.

This is the story they didn't want you to read.

What the Studies Are Actually Saying

For years, the official line from major medical bodies was clear and confident: regret rates among people who undergo gender transition are extremely low, often cited at around 1%. This figure was repeated so frequently and with such authority that questioning it felt almost taboo.

But where did that number come from? And does it hold up?

A closer look at the research tells a more complicated story.

Many of the foundational studies used to establish "low regret" figures suffered from serious methodological flaws, small sample sizes, short follow-up periods, high dropout rates, and in some cases, the exclusion of patients who couldn't be located, including those who may have had the worst outcomes.

A landmark 2021 systematic review published in the journal LGBT Health found that studies on regret were limited by inconsistent methodology and that many participants were simply lost to follow-up. A person who quietly detransitions and disappears from the clinic's records does not show up as a "regret" statistic. They vanish.

More recently, Sweden's Karolinska Institute,  one of the most prestigious medical research bodies in the world, conducted a long-term review of outcomes for people who underwent gender-affirming surgery. The results were sobering enough that Sweden subsequently overhauled its entire approach to youth gender medicine, restricting hormonal interventions for minors except in the most exceptional clinical circumstances.

Finland followed. Denmark followed. England's NHS followed, commissioning the landmark Cass Review, a four-year independent investigation led by Dr. Hilary Cass, a former president of the Royal College of Paediatrics and Child Health.

The Cass Review, published in 2024, was scathing. It found that the evidence base supporting puberty blockers and cross-sex hormones for children and adolescents was extraordinarily weak, far below what would be acceptable for any other medical intervention. It described a clinical environment in which ideological pressure had overridden proper scientific scrutiny, and in which young patients had been fast-tracked into irreversible treatments without adequate psychological assessment.

Pause on that for a moment. An independent review commissioned by England's own National Health Service concluded that the evidence for these interventions was, in the reviewers' words, "remarkably weak."

The Detransitioners: Faces Behind the Numbers

Statistics are cold. The human stories behind them are not.

In recent years, a growing community of detransitioners, people who underwent gender transition and later returned to identifying with their birth sex, has emerged online and in public discourse. They are not a monolith. Their experiences are varied, their reasons for transitioning were different, and their paths back have been painful in their own unique ways.

But their voices share certain recurring themes that are impossible to dismiss.

Many describe being affirmed rapidly, sometimes in a single appointment, into a path that would result in surgical removal of healthy body parts or lifelong hormonal dependency. Many describe underlying trauma, autism spectrum conditions, or mental health struggles that they now believe were the true driving forces behind their dysphoria, but which were never adequately explored. Many say they were told that the alternative to transition was suicide, a claim that, as emerging evidence increasingly suggests, was not supported by the data in the way it was presented.

Chloe Cole, an American woman who began transitioning at 12 and had a double mastectomy at 15, has become one of the most prominent voices in this space. She has testified before legislatures, spoken at medical conferences, and described in raw, unflinching detail the physical and psychological consequences of decisions made on her behalf when she was a child who could not possibly have understood their permanence.

Helena Kerschner, Ritchie Herron, Cat Cattinson, these names are increasingly well-known among those paying attention. Their stories are not fringe anecdotes. They are documented testimonies that demand a serious institutional response.

And yet, for years, the institutional response was to call them liars. Or transphobic. Or tools of a right-wing agenda.

The cruelty of that dismissal should not be underestimated.

The Medical Ethics Failure

Let us be precise about what is being alleged here, because precision matters.

This is not a claim that all gender transition is wrong, or that nobody should be allowed to pursue it, or that trans people do not exist or do not suffer. Adults with persistent, well-assessed gender dysphoria are entitled to make autonomous decisions about their own bodies, and that right is not in question here.

What is in question is whether the medical institutions entrusted with protecting vulnerable patients, particularly children and adolescents, have fulfilled their duty of care.

The evidence strongly suggests they have not.

Medical ethics rests on four foundational pillars: autonomy, beneficence, non-maleficence, and justice. The principle of non-maleficence, first, do no harm, demands that before any intervention is offered, the evidence for its benefit must outweigh the evidence for its harm. Particularly when the intervention is irreversible. Particularly when the patient is a minor.

By that standard, the clinical practices of the past decade in gender medicine represent one of the most significant failures of institutional medicine in living memory.

Puberty blockers, once described as "fully reversible", a claim now abandoned even by many of their former advocates , were prescribed to thousands of adolescents with minimal long-term data on their effects on bone density, neurological development, cardiovascular health, and future fertility. The children and parents who were told these drugs simply pressed pause on puberty were not told that in study after study, the overwhelming majority of young people placed on puberty blockers went on to cross-sex hormones, a trajectory that raises serious questions about what "reversible" was ever supposed to mean.

In the United Kingdom, the Tavistock Gender Identity Development Service, for years the only NHS clinic for young people with gender dysphoria, is now the subject of a major class-action lawsuit brought by families who allege that their children were harmed by negligent care. The clinic was closed in 2022 following the interim findings that would eventually become the full Cass Review.

In the United States, WPATH....the World Professional Association for Transgender Health, the body whose guidelines most American gender clinics followed, released internal communications through legal discovery in 2024 that showed significant internal disagreement about the evidence base, particularly for pediatric care, that was never made public in its official guidance.

Institutional medicine failed these patients. That is not a political statement. It is a finding.

Why Was It So Hard to Say?

This is perhaps the most important question of all, and answering it honestly requires confronting some uncomfortable truths about how modern institutions work.

A combination of social pressure, activist influence on medical bodies, media suppression of dissenting voices, and the genuine desire not to be seen as hostile to a vulnerable community created a climate in which critical inquiry was systematically discouraged. Researchers who raised concerns about evidence quality found their funding dried up, their careers threatened, and their reputations attacked. Clinicians who urged caution were labeled transphobic. Parents who asked questions were told they were putting their children at risk.

Science cannot function in that environment. Medicine cannot protect patients in that environment.

The result was a generation of young people, many of them gay, many of them autistic, many of them girls with histories of trauma and anxiety, who were processed through a clinical pipeline that prioritized affirmation over investigation, speed over caution, and ideological consistency over scientific integrity.

The Reckoning Is Coming

Across the Western world, the reckoning is already underway.

Sweden, Finland, Denmark, Norway, and the United Kingdom have all moved to restrict or significantly reform youth gender medicine based on reviews of the evidence. Legal cases are multiplying. Former patients are suing the clinics that treated them. Medical professionals who were silenced for years are now speaking publicly.

The conversation that powerful institutions tried to prevent is happening anyway.

What is owed now, to the detransitioners who were gaslit and dismissed, to the families who were told their concerns were bigotry, to the young people who are now navigating the long-term consequences of interventions that were presented as lifesaving and straightforward, is honesty.

Full, unflinching, institutional honesty.

Not political spin. Not damage control. Not another wave of suppression dressed up as compassion.

The scandal was not that people asked hard questions.

The scandal is that for so long, no one in power was willing to answer them.